Scleroderma-related lung disease: are adipokines involved pathogenically?

Area of Science:

• Immunology
• Endocrinology
• Pulmonology

Background:

• Scleroderma is a systemic autoimmune disease with unknown causes.
• Lung complications like interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are leading causes of death in scleroderma patients.
• The molecular basis of scleroderma-related lung disease is not well understood, but circulating factors are implicated.

Purpose of the Study:

• To investigate the potential role of adipokines in the pathogenesis of scleroderma-related lung diseases.
• To explore how adipokines like adiponectin and leptin influence cells involved in ILD and PAH.

Main Methods:

• Review of current literature on scleroderma, adipokines, and lung disease.
• Analysis of the known biological activities of adiponectin and leptin on relevant cell types.

Main Results:

• Adipokines, particularly adiponectin and leptin, are altered in scleroderma.
• These adipokines regulate endothelial, fibroblast, and immune cells crucial to lung tissue.
• Their widespread effects suggest a mechanistic link to ILD and PAH in scleroderma.

Conclusions:

• Adipokines represent a novel class of circulating factors potentially involved in scleroderma-associated lung pathology.
• Adiponectin and leptin warrant further investigation as therapeutic targets for scleroderma-related lung diseases.